New Findings on Cancer and Alzheimer’s Disease Connection

Cancer and Alzheimer’s disease are among the most daunting medical diagnoses, yet they seldom occur in the same individual. Epidemiologists have long observed a curious trend: individuals with cancer often seem less prone to Alzheimer’s, while those with Alzheimer’s are less frequently diagnosed with cancer. The reason behind this phenomenon has remained a mystery—until now.

A recent study using mice offers a surprising insight. It suggests that certain cancers could send a protective signal to the brain, aiding in the removal of toxic protein clusters associated with Alzheimer’s disease.

Alzheimer’s is defined by the accumulation of amyloid beta protein deposits between nerve cells in the brain. These sticky plaques disrupt communication among nerve cells, leading to inflammation and damage that gradually impairs memory and cognitive function.

In this latest research, scientists implanted human lung, prostate, and colon tumors under the skin of mice specifically bred to develop Alzheimer-like amyloid plaques. Typically, these mice accumulate significant amyloid beta as they age, reflecting a hallmark of the human condition.

However, when these mice had tumors, the usual plaque accumulation reduced significantly. Some tests even indicated improvements in memory for the mice with tumors compared to those without, hinting at changes beyond molecular observations.

The researchers pinpointed a protein called cystatin‑C, which was secreted by the tumors into the bloodstream. Their findings indicate that, at least in mice, cystatin‑C can cross the blood-brain barrier, which ordinarily restricts many substances from entering the brain.

Once inside, cystatin‑C seems to attach to small clusters of amyloid beta, tagging them for destruction by the brain’s immune cells, known as microglia. These cells are like a cleanup crew for the brain, constantly searching for debris and misfolded proteins.

In Alzheimer’s, microglia appear to struggle, allowing amyloid beta to accumulate and form plaques. In mice with tumors, cystatin‑C activated a sensor on microglia called Trem2, enabling them to become more effective in clearing plaques.

Unexpected Trade-offs

At first, it might seem bizarre to think a cancer could potentially protect the brain against dementia. Yet, biology often operates through trade-offs, where a harmful process in one setting may yield benefits in another.

In this context, the secretion of cystatin‑C by tumors might be an unintended consequence that actually helps the brain address issues with misfolded proteins. This discovery doesn’t suggest that having cancer is beneficial; rather, it opens a potential pathway for safe scientific exploration.

This study adds to a growing body of research indicating that the link between cancer and neurodegenerative conditions is more profound than mere coincidence. Larger population studies have shown that those with Alzheimer’s are notably less likely to develop cancer, and the reverse is also true, even when factoring in age and other health considerations.

Some researchers propose a biological seesaw, where mechanisms promoting survival and growth, such as those in cancer, may deter paths leading to brain degeneration. The findings related to cystatin‑C enhance this understanding by providing a physical mechanism.

Of course, this research was conducted in mice, which differs significantly from humans. Mouse models capture certain traits of Alzheimer’s, like amyloid plaques, but they don’t fully encapsulate the complexity of the human experience of dementia.

We still need to determine if cancers in humans produce enough cystatin‑C or transport it to the brain similarly to how it occurred in mice to affect Alzheimer’s risk meaningfully. Yet, this discovery presents intriguing possibilities for future treatments.

One idea is to create drugs or therapies that replicate the beneficial effects of cystatin‑C without involving tumors. This could entail engineered versions of the protein to bind amyloid beta more effectively or molecules that activate the same pathways in microglia to enhance their cleanup abilities.

This research also underscores the interconnectedness of diseases, even those affecting vastly different organs. A tumor situated in the lung or colon may seem unrelated to the gradual accumulation of protein deposits in the brain, yet the substances released by that tumor can navigate the bloodstream, cross barriers, and alter brain cell functions.

For individuals with cancer or caregivers for those with Alzheimer’s, this study won’t lead to immediate changes in treatment. However, it does convey a more optimistic perspective: in examining rigorous subjects like cancer, researchers can uncover surprising insights that might eventually support brain health in later years.

Perhaps the overarching lesson here is that the body’s defenses and vulnerabilities are rarely straightforward. A protein contributing to disease in one area could serve as a cleanup mechanism in another. By comprehending these nuances, researchers may find safe ways to bolster protections for the aging brain.